WallStSmart

Merck & Company Inc (MRK)vsNeogen Corporation (NEOG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 7548% more annual revenue ($66.57B vs $870.40M). MRK leads profitability with a 4.8% profit margin vs -0.9%. NEOG appears more attractively valued with a PEG of 0.66. NEOG earns a higher WallStSmart Score of 41/100 (D).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

NEOG

Hold

41

out of 100

Grade: D

Growth: 2.7Profit: 2.5Value: 7.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.24
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued
NEOGUndervalued (+80.7%)

Margin of Safety

+80.7%

Fair Value

$55.73

Current Price

$11.78

$43.95 discount

UndervaluedFair: $55.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

NEOG2 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

NEOG4 concerns · Avg: 2.3/10
Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Return on EquityProfitability
-29.0%2/10

ROE of -29.0% — below average capital efficiency

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

EPS GrowthGrowth
-85.6%2/10

Earnings declined 85.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : NEOG

The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : NEOG

The primary concerns for NEOG are Operating Margin, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while NEOG is a turnaround play — different risk/reward profiles.

NEOG carries more volatility with a beta of 1.76 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

NEOG scores higher overall (41/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Neogen Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.

Visit Website →

Want to dig deeper into these stocks?